Heavy Light Chain in Chronic Lymphocytic Leukemia

NCT ID: NCT02377869

Last Updated: 2015-03-04

Basic Information

• Recruitment Status: UNKNOWN
• Total Enrollment: 130 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2015-01-31
• Study Completion Date: 2020-01-31

Brief Summary

Recently, a novel assay for detecting heavy/light chain (HLC) ratios has been reported which enables improvement in paraprotein detection and monitoring in multiple myeloma and other plasma-cell dyscrasias.

The prognostic and biological role of the HLC assay has as yet not been studied in CLL.

Aims of the proposed study:

1. To quantify and analyze the prognostic significance of HLC ratios in the serum of CLL patients. (In addition to FLC)

2. To study the different patterns of Immunoglobulin's subclass antibodies in the serum of patients with CLL and compare them to those of to healthy volunteers.

3. To perform a sub-analysis in patients with CLL who have autoimmune phenomenon (AIHA and ITP)

Detailed Description

Analysis of immunoglobulin heavy/light chain pairs In chronic lymphocytic leukemia

Introduction and Background:

Chronic Lymphocytic Leukemia (CLL) is the most common type of leukemia in the western world. Median age at diagnosis is 72 years, and the male to female ratio is 2:1. The disease is characterized by an accumulation of monoclonal mature B-cells which co-express the T-cell antigen CD5, B-cell surface antigens CD19, CD20, and CD23(1) and either kappa or lambda immunoglobulin light chains restriction (2). Diagnosis is established based on the IWCLL criteria published by Hallek at al in 2008. (1).

CLL may have a heterogeneous clinical course with a wide spectrum of manifestations ranging from long lived asymptomatic patients who never require treatment to those with a more rapid clinical course and symptomatic progression. One of the remaining important challenges in CLL is to stratify patients into different prognostic categories, so as to plan appropriate targeted therapy when necessary . The most important prognostic factor in CLL relates to the presence of typical genomic aberrations in the leukemic cell (3). Other essential prognostic parameters include: CD38 expression, the presence of ZAP-70, immunoglobulin heavy chain mutational status, and beta 2 microglobulin (B2MG) levels. (1).

Patients with CLL, have a 10 % risk of developing autoimmune complications mostly auto-immune hemolytic anemia (AIHA) and immune thrombocytopenia (ITP) (4-6). The pathogenesis for these autoimmune cytopenias is linked to the production of polyclonal immunoglobulin G (IgG) antibodies (less frequently IgM) directed against a variety of red blood cell or platelet antigens. (4-6).

The use of serum free light chain (FLC) levels as an important prognostic tool in different plasma cell dyscrasias is already well established (75) while the prognostic significance of FLC in CLL has only been reported more recently by few publications (8-10). Furthermore, Tsai et al, have also described that serum FLC abnormalities may precede diagnosis in 38 % of patients with CLL (11).

Recently, a novel assay for detecting heavy/light chain (HLC) ratios has been reported which enables improvement in paraprotein detection and monitoring in multiple myeloma and other plasma-cell dyscrasias. (12-13).

The prognostic and biological role of the HLC assay has as yet not been studied in CLL.

Aims of the proposed study:

1. To quantify and analyze the prognostic significance of HLC ratios in the serum of CLL patients. (In addition to FLC)

2. To study the different patterns of Immunoglobulin's subclass antibodies in the serum of patients with CLL and compare them to those of to healthy volunteers.

3. To perform a sub-analysis in patients with CLL who have autoimmune phenomenon (AIHA and ITP)

Materials and methods:

The study will be performed in collaboration with the Israeli CLL Study Group.

All patients included will have complete clinical database available and medical records summarized.

Baseline laboratory parameters to be examined will include: complete blood count, Coombs test, serum B2MG and LDH, Immunoglobulin levels,, flow-cytometry including CD38 expression and ZAP70 and urine Bence Jones protein.

Frozen serum samples from CLL patients will be analyzed for levels of:

• Free light chain: kappa/lambda, ratio of K/L and total sum of K+L.
• IgG1, IgG2, IgG3, IgG4.
• Isoforms of heavy/light chain of IgG kappa, IgG lambda, IgA kappa, IgA lambda, IgM kappa, IgM lambda

References:

1. Michael Hallek, Bruce D. Cheson, Daniel Catovsky, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood. Jun 15, 2008; 111(12): 5446-5456.

2. Moreau EJ, Matutes E, A'Hern RP, et al. Improvement of the chronic lymphocytic leukemia scoring system with the monoclonal antibody SN8 (CD79b). Am J Clin Pathol.1997;108:378-382.

3. Döhner H, Stilgenbauer S, Benner A, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med. 2000 Dec 28; 343(26):1910-6.

4. Hamblin TJ, Oscier DG, Young BJ. Autoimmunity in chronic lymphocytic leukemia. J Clin Pathol 1986;39;713-16

5. Zent CS, Kay NE. Autoimmune complications in chronic lymphocytic leukaemia (CLL). Best Pract Res Clin Haematol. 2010 Mar;23(1):47-59.

6. Visco C, Barcellini W, Maura F, Neri A, Cortelezzi A, Rodeghiero F. Autoimmune cytopenias in chronic lymphocytic leukemia. Am J Hematol. 2014 Jun 10

7. Dispenzieri A, Kyle R, Merlini G, et al. International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. Leukemia. 2009 Feb;23(2):215-24.

8. Maurer MJ, Cerhan JR, Katzmann JA, et al. Monoclonal and polyclonal serum free light chains and clinical outcome in chronic lymphocytic leukemia. Blood. 2011 Sep 8;118(10):2821-6

9. Morabito F, De Filippi R, Laurenti L, et al. The cumulative amount of serum-free light chain is a strong prognosticator in chronic lymphocytic leukemia. Blood. 2011 Dec 8;118(24):6353-61.

10. Sarris K, Maltezas D, Koulieris E, et al. Prognostic significance of serum free light chains in chronic lymphocytic leukemia. Adv Hematol. 2013;2013:359071

11. Tsai HT, Caporaso NE, Kyle RA, et al. Evidence of serum immunoglobulin abnormalities up to 9.8 years before diagnosis of chronic lymphocytic leukemia: a prospective study. Blood. 2009 Dec 3;114(24):4928-32

12. Ludwig H, Milosavljevic D, Zojer N, et al. Immunoglobulin heavy/light chain ratios improve paraprotein detection and monitoring, identify residual disease and correlate with survival in multiple myeloma patients. Leukemia. 2013 Apr;27(4):996.

13. Katzmann JA, Clark R, Kyle RA, et al. Suppression of uninvolved immunoglobulins defined by heavy/light chain pair suppression is a risk factor for progression of MGUS. Leukemia. 2013 Jan;27(1):208-12.

Conditions

CLL

Study Design

• Observational Model Type: COHORT
• Study Time Perspective: PROSPECTIVE

Interventions

No intervantion

Intervention Type: OTHER

Eligibility Criteria

Inclusion Criteria

New diagnosed patients with CLL (untreated)

Exclusion Criteria

Not treated with immunoglobulin Not treated with steroids

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Rambam Health Care Campus

OTHER

Sponsor Role: collaborator

Laniado Hospital

OTHER

Sponsor Role: collaborator

Meir Medical Center

OTHER

Sponsor Role: collaborator

Rabin Medical Center

OTHER

Sponsor Role: collaborator

Kaplan Medical Center

OTHER

Sponsor Role: collaborator

Shaare Zedek Medical Center

OTHER

Sponsor Role: collaborator

Hadassah Medical Organization

OTHER

Sponsor Role: collaborator

HaEmek Medical Center, Israel

OTHER

Sponsor Role: collaborator

Western Galilee Hospital-Nahariya

OTHER_GOV

Sponsor Role: collaborator

Tel-Aviv Sourasky Medical Center

OTHER_GOV

Sponsor Role: collaborator

Assaf-Harofeh Medical Center

OTHER_GOV

Sponsor Role: collaborator

Bnai Zion Medical Center

OTHER_GOV

Sponsor Role: lead

Responsible Party

tamar.tadmor

MD

Responsibility Role: PRINCIPAL_INVESTIGATOR

Locations

Bnai Zion Medical Center

Haifa, Israel, Israel

Site Status: RECRUITING

Countries

Israel

Facility Contacts

Tamar Tadmor, MD

Role: primary

tamar.tadmor@b-zion.org.il

+97248359 ext. 407

Other Identifiers

0018-14-BNZ

Identifier Type: -

Identifier Source: org_study_id